Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Oral EDP-514 is a potent core protein inhibitor of hepatitis B virus (HBV) replication, which produced a >4-log viral load reduction in HBV-infected chimeric mice with human liver cells. This study evaluated the safety, pharmacokinetics, and antiviral activity of three doses of EDP-514 in treatment-naive viremic patients with HBeAg-positive or -negative chronic HBV infection. Methods: Patients with HBsAg detectable at screening and at least 6 months previously were eligible. HBeAg-positive and -negative patients had a serum/plasma HBV DNA level ≥20,000 and ≥2,000 IU/mL, respectively. Twentyfive patients were randomized to EDP-514 200 (n=6), 400 (n=6) or 800 mg (n=7) or placebo (n=6) once daily for 28 days. Results: A dose-related increase in EDP-514 exposure (AUClast and Cmax) was observed across doses. At Day 28, mean reductions in HBV DNA were –2.9, –3.3, –3.5 and –0.2 log10 IU/mL with EDP-514 200 mg, 400 mg, 800 mg, and placebo groups, respectively. The corresponding mean change from baseline for HBV RNA levels was –2.9, –2.4, –2.0, and –0.02 log10 U/mL. No virologic failures were observed. No clinically meaningful changes from baseline were observed for HBsAg, HBeAg or HBcrAg. Nine patients reported treatment emergent adverse events of mild or moderate severity with no discontinuations, serious AEs or deaths. Conclusions: In treatment-naïve viremic patients, oral EDP-514 was generally safe and well-tolerated, displayed PK profile supportive of once-daily dosing, and markedly reduced HBV DNA and HBV RNA.
Abstract
Background/Aims: Oral EDP-514 is a potent core protein inhibitor of hepatitis B virus (HBV) replication, which produced a >4-log viral load reduction in HBV-infected chimeric mice with human liver cells. This study evaluated the safety, pharmacokinetics, and antiviral activity of three doses of EDP-514 in treatment-naive viremic patients with HBeAg-positive or -negative chronic HBV infection. Methods: Patients with HBsAg detectable at screening and at least 6 months previously were eligible. HBeAg-positive and -negative patients had a serum/plasma HBV DNA level ≥20,000 and ≥2,000 IU/mL, respectively. Twentyfive patients were randomized to EDP-514 200 (n=6), 400 (n=6) or 800 mg (n=7) or placebo (n=6) once daily for 28 days. Results: A dose-related increase in EDP-514 exposure (AUClast and Cmax) was observed across doses. At Day 28, mean reductions in HBV DNA were –2.9, –3.3, –3.5 and –0.2 log10 IU/mL with EDP-514 200 mg, 400 mg, 800 mg, and placebo groups, respectively. The corresponding mean change from baseline for HBV RNA levels was –2.9, –2.4, –2.0, and –0.02 log10 U/mL. No virologic failures were observed. No clinically meaningful changes from baseline were observed for HBsAg, HBeAg or HBcrAg. Nine patients reported treatment emergent adverse events of mild or moderate severity with no discontinuations, serious AEs or deaths. Conclusions: In treatment-naïve viremic patients, oral EDP-514 was generally safe and well-tolerated, displayed PK profile supportive of once-daily dosing, and markedly reduced HBV DNA and HBV RNA.
참고문헌 (32)
- Prifti GM, "Recent advances in hepatitis B treatment", Pharmaceuticals(Basel), 14, pp.417~ (2021)
- "World Health Organization Hepatitis B-Key Facts"[URL]
- European Association for the Study of the Liver, "EASL 2017Clinical Practice Guidelines on the management of hepatitis B virus infection", J Hepatol, 67, pp.370~398 (2017)
- Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B : AASLD 2018 hepatitis B guidance", Hepatology, 67, pp.1560~1599 (2018)
- Dusheiko G, "Hepatitis B cure : How and when", Liver Int, 41(Suppl 1), pp.24~29 (2021)
- Tsounis EP, "Toward a new era of hepatitis B virus therapeutics : The pursuit of a functional cure", World J Gastroenterol, 27, pp.2727~2757 (2021)
- Gish RG, "Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent", Antiviral Res, 121, pp.97~108 (2015)
- Zoulim F, "Antiviral therapies and prospects for a cure of chronic hepatitis B", Cold Spring Harb Perspect Med, 5, pp.a021501~ (2015)
- Park H, "Economic and clinical burden of viral hepatitis in California : A population-based study with longitudinal analysis", PLoS One, 13, pp.e0196452~ (2018)
- Sbarigia U, "Evaluating the effect of standard of care treatment on burden of chronic hepatitis B : A retrospective analysis of the United States Veterans population", Adv Ther, 37, pp.1156~1172 (2020)
- Dandri M, "cccDNA Maintenance in chronic hepatitis B-Targeting the matrix of viral replication", Infect Drug Resist, 13, pp.3873~3886 (2020)
- Testoni B, "Novel targets for hepatitis B virus therapy", Liver Int, 37(Suppl 1), pp.33~39 (2017)
- Zhang X, "Discovery of novel hepatitis B virus nucleocapsid assembly inhibitors", ACS Infect Dis, 5, pp.759~768 (2019)
- Yuen MF, "Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor : a randomised, placebo-controlled phase 1 trial", Lancet Gastroenterol Hepatol, 5, pp.152~166 (2020)
- Yuen MF, "Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection : a multicentre, randomised, placebo-controlled, phase 1 trial", Lancet Gastroenterol Hepatol, 6, pp.723~732 (2021)
- Zoulim F, "JNJ-56136379, an HBV capsid assembly modulator, is well-tolerated and has antiviral activity in a phase 1 study of patients with chronic infection", Gastroenterology, 159, pp.521~533 (2020)
- Vaine M, "FRI-191-EDP-514, a novel HBV core inhibitor with potent antiviral activity both in vitro and in vivo", J Hepatol, 70, pp.e474~e475 (2019)
- Feld JJ, "EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B", Antivir Ther, 27, pp.13596535221127848~ (2022)
- Levrero M, "Control of cccDNA function in hepatitis B virus infection", J Hepatol, 51, pp.581~592 (2009)
- Chain BM, "Variability and conservation in hepatitis B virus core protein", BMC Microbiol, 5, pp.33~ (2005)
- Mak LY, "HBV RNA profiles in patients with chronic hepatitis B under different disease phases and antiviral therapy", Hepatology, 73, pp.2167~2179 (2021)
- Gane EJ, "Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection", J Antimicrob Chemother, 77, pp.1102~1110 (2022)
- Zhang H, "Randomised clinical trial : safety, efficacy and pharmacokinetics of HS-10234 versus tenofovir for the treatment of chronic hepatitis B infection", Aliment Pharmacol Ther, 53, pp.243~252 (2021)
- Sulkowski MS, "Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection", J Hepatol, 77, pp.1265~1275 (2022)
- Giersch K, "Serum HBV pgRNA as a clinical marker for cccDNA activity", J Hepatol, 66, pp.460~462 (2017)
- Jansen L, "Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon alfa-2a and nucleos(t)ide analogues", J Infect Dis, 213, pp.224~232 (2016)
- Tsuge M, "Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients", J Gastroenterol, 48, pp.1188~1204 (2013)
- van Bömmel F, "Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors", Hepatology, 61, pp.66~76 (2015)
- Wang J, "Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound", J Hepatol, 65, pp.700~710 (2016)
- Yuen MF, "Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection", J Hepatol, 77, pp.642~652 (2022)
- Hou J, "ALG-000184, a capsid assembly modulator, dosed with entecavir for up to 28 weeks is well tolerated and resulted in substantial declines in surface antigen levels in untreated hepatitis B e antigen positive subjects with chronic hepatitis", Paper presented at: 2023 European Association for the Study of the Liver (2023)
- Yuen M-F, "Safety, pharmacokinetics, and antiviral activity of the class II capsid assembly modulator ALG-000184 in subjects with chronic hepatitis B", J Hepatol, 77(Suppl), pp.S835~S836 (2022)